- Advertisement -
Melbourne-based bowel cancer diagnostics developer Rhythm Biosciences (ASX: RHY) has acquired the GeneType disease prediction business for $625,000 from Genetic Technologies (ASX: GTG), which entered administration last month after falling short in an attempted $2 million capital raise.
Documents…
